Living-Donor Pancreas Transplantation. Progress, Pitfalls, and Promise.

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pancreas transplants using living donors (LDs) can be done safely and successfully in carefully selected donors and recipients. Worldwide, since 1979, more than 150 LD pancreas transplants have been done; over the last decade, the overall 1-year graft survival rates have exceeded 85%. A meticulous donor workup, per standard evaluation criteria, remains key to a low rate of metabolic and surgical complications in LDs. Such transplants should be considered for (i) candidates with an identical twin or a human leukocyte antigen (HLA)-identical sibling or (ii) candidates with high panel-reactive antibody levels and a suitable LD. The use of LDs decreases the number of deaths of diabetic patients on the waiting list, helps to overcome the organ shortage, reduces mortality and morbidity posttransplant, and improves the quality of life for recipients who, pretransplant, suffered debilitating side effects of diabetes. In addition, the use of LDs (vs. deceased donors) reduces the risk of graft loss from rejection. An LD pancreas transplant remains relatively rare, done under very specific circumstances.

Original languageEnglish (US)
Title of host publicationRegenerative Medicine Applications in Organ Transplantation
PublisherElsevier Inc.
Pages571-581
Number of pages11
ISBN (Print)9780123985231
DOIs
StatePublished - 2014

Fingerprint

Transplantation (surgical)
Pancreas Transplantation
Transplants
Living Donors
Grafts
Pancreas
Tissue Donors
Medical problems
HLA Antigens
Waiting Lists
Monozygotic Twins
Graft Rejection
Graft Survival
Antibodies
Siblings
Survival Rate
Quality of Life
Morbidity
Mortality

Keywords

  • LD
  • Living donor
  • Pancreas transplantation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Gruessner, R. W. G., Sutherland, D. E. R., & Gruessner, A. C. (2014). Living-Donor Pancreas Transplantation. Progress, Pitfalls, and Promise. In Regenerative Medicine Applications in Organ Transplantation (pp. 571-581). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-398523-1.00039-2

Living-Donor Pancreas Transplantation. Progress, Pitfalls, and Promise. / Gruessner, Rainer W G; Sutherland, David E R; Gruessner, Angelika C.

Regenerative Medicine Applications in Organ Transplantation. Elsevier Inc., 2014. p. 571-581.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gruessner, RWG, Sutherland, DER & Gruessner, AC 2014, Living-Donor Pancreas Transplantation. Progress, Pitfalls, and Promise. in Regenerative Medicine Applications in Organ Transplantation. Elsevier Inc., pp. 571-581. https://doi.org/10.1016/B978-0-12-398523-1.00039-2
Gruessner RWG, Sutherland DER, Gruessner AC. Living-Donor Pancreas Transplantation. Progress, Pitfalls, and Promise. In Regenerative Medicine Applications in Organ Transplantation. Elsevier Inc. 2014. p. 571-581 https://doi.org/10.1016/B978-0-12-398523-1.00039-2
Gruessner, Rainer W G ; Sutherland, David E R ; Gruessner, Angelika C. / Living-Donor Pancreas Transplantation. Progress, Pitfalls, and Promise. Regenerative Medicine Applications in Organ Transplantation. Elsevier Inc., 2014. pp. 571-581
@inbook{70a539d2086647218e34a6ee492e88b2,
title = "Living-Donor Pancreas Transplantation. Progress, Pitfalls, and Promise.",
abstract = "Pancreas transplants using living donors (LDs) can be done safely and successfully in carefully selected donors and recipients. Worldwide, since 1979, more than 150 LD pancreas transplants have been done; over the last decade, the overall 1-year graft survival rates have exceeded 85{\%}. A meticulous donor workup, per standard evaluation criteria, remains key to a low rate of metabolic and surgical complications in LDs. Such transplants should be considered for (i) candidates with an identical twin or a human leukocyte antigen (HLA)-identical sibling or (ii) candidates with high panel-reactive antibody levels and a suitable LD. The use of LDs decreases the number of deaths of diabetic patients on the waiting list, helps to overcome the organ shortage, reduces mortality and morbidity posttransplant, and improves the quality of life for recipients who, pretransplant, suffered debilitating side effects of diabetes. In addition, the use of LDs (vs. deceased donors) reduces the risk of graft loss from rejection. An LD pancreas transplant remains relatively rare, done under very specific circumstances.",
keywords = "LD, Living donor, Pancreas transplantation",
author = "Gruessner, {Rainer W G} and Sutherland, {David E R} and Gruessner, {Angelika C}",
year = "2014",
doi = "10.1016/B978-0-12-398523-1.00039-2",
language = "English (US)",
isbn = "9780123985231",
pages = "571--581",
booktitle = "Regenerative Medicine Applications in Organ Transplantation",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Living-Donor Pancreas Transplantation. Progress, Pitfalls, and Promise.

AU - Gruessner, Rainer W G

AU - Sutherland, David E R

AU - Gruessner, Angelika C

PY - 2014

Y1 - 2014

N2 - Pancreas transplants using living donors (LDs) can be done safely and successfully in carefully selected donors and recipients. Worldwide, since 1979, more than 150 LD pancreas transplants have been done; over the last decade, the overall 1-year graft survival rates have exceeded 85%. A meticulous donor workup, per standard evaluation criteria, remains key to a low rate of metabolic and surgical complications in LDs. Such transplants should be considered for (i) candidates with an identical twin or a human leukocyte antigen (HLA)-identical sibling or (ii) candidates with high panel-reactive antibody levels and a suitable LD. The use of LDs decreases the number of deaths of diabetic patients on the waiting list, helps to overcome the organ shortage, reduces mortality and morbidity posttransplant, and improves the quality of life for recipients who, pretransplant, suffered debilitating side effects of diabetes. In addition, the use of LDs (vs. deceased donors) reduces the risk of graft loss from rejection. An LD pancreas transplant remains relatively rare, done under very specific circumstances.

AB - Pancreas transplants using living donors (LDs) can be done safely and successfully in carefully selected donors and recipients. Worldwide, since 1979, more than 150 LD pancreas transplants have been done; over the last decade, the overall 1-year graft survival rates have exceeded 85%. A meticulous donor workup, per standard evaluation criteria, remains key to a low rate of metabolic and surgical complications in LDs. Such transplants should be considered for (i) candidates with an identical twin or a human leukocyte antigen (HLA)-identical sibling or (ii) candidates with high panel-reactive antibody levels and a suitable LD. The use of LDs decreases the number of deaths of diabetic patients on the waiting list, helps to overcome the organ shortage, reduces mortality and morbidity posttransplant, and improves the quality of life for recipients who, pretransplant, suffered debilitating side effects of diabetes. In addition, the use of LDs (vs. deceased donors) reduces the risk of graft loss from rejection. An LD pancreas transplant remains relatively rare, done under very specific circumstances.

KW - LD

KW - Living donor

KW - Pancreas transplantation

UR - http://www.scopus.com/inward/record.url?scp=84902894330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902894330&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-398523-1.00039-2

DO - 10.1016/B978-0-12-398523-1.00039-2

M3 - Chapter

SN - 9780123985231

SP - 571

EP - 581

BT - Regenerative Medicine Applications in Organ Transplantation

PB - Elsevier Inc.

ER -